← Leaderboards
Michael S. Diamond
University Of Pittsburgh At Pittsburgh
$85,358,908
Attributed
$135,890,356
Total exposure
44
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $63.9M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$198,073,475 · 47
By mechanism
R01$91,080,502 · 25
U19$74,636,241 · 8
U01$14,596,662 · 5
P01$14,384,327 · 3
U54$1,995,455 · 2
UH3$462,414 · 1
Top collaborators
- Daved H Fremont25 shared
- James E Crowe22 shared
- Richard J. Kuhn15 shared
- Thomas E Morrison12 shared
- Carolyn B Coyne10 shared
- Michael J Gale10 shared
- Robyn S Klein10 shared
- Scott A. Handley9 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Nicole McAllister$84,720
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionVirusVirus DiseasesViralDiamondCellsIn VivoLaboratoriesMediatingPathogenesisVaccinesBaseAntibodiesMouse ModelImmuneMolecularExperimental StudyResponseWest Nile VirusFlavivirusPathogenAntiviral AgentsCulicidaeBinding
Grant awards (188)
Structure-Function Analysis of Mxra8 Interaction with Alphaviruses$3,371,896
R01 · FY2025 · AI · contact PI
The Development and Evaluation of Pan-Coronavirus Vaccines$2,716,452
P01 · FY2025 · AI · contact PI
Mechanisms of Immune Protection Against Respiratory Viruses$2,380,350
U19 · FY2025 · AI
ANTIBODY-BASED PROTECTION AGAINST FLAVIVIRUSES$1,111,778
U01 · FY2025 · AI · contact PI
Regulation Of Lung Immunity By Antibody Glycosylation$860,851
R01 · FY2025 · AI
Development of Viral Vaccines against Sarbecoviruses and Merbecoviruses$844,055
P01 · FY2025 · AI · contact PI
Alphavirus Pathogenesis and Immunity$782,871
R01 · FY2025 · AI
Human Monoclonal Antibodies for Encephalitic Alphaviruses$781,163
R01 · FY2025 · AI
Meningeal Immunity and Viral Neuropathogenesis$769,115
R01 · FY2025 · AI · contact PI
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus$762,686
R01 · FY2025 · AI · contact PI
Pathogenesis of Alphavirus induced Chronic Arthritis and Myositis$754,069
R01 · FY2025 · AI
Project 2$696,607
U19 · FY2025 · AI · contact PI
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis$652,163
R01 · FY2025 · AI · contact PI
Administrative Core$163,930
P01 · FY2025 · AI · contact PI
Flavivirus and Alphavirus ReVAMPP (FLARE)$46,715,173
U19 · FY2024 · AI · contact PI
Core E: Correlates of Protection$5,678,163
U19 · FY2024 · AI · contact PI
Mechanisms of Immune Protection Against Respiratory Viruses$2,380,350
U19 · FY2024 · AI
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2$1,193,360
R01 · FY2024 · AI · contact PI
Core A: Administrative$1,113,173
U19 · FY2024 · AI · contact PI
ANTIBODY-BASED PROTECTION AGAINST FLAVIVIRUSES$1,101,100
U01 · FY2024 · AI · contact PI
Regulation Of Lung Immunity By Antibody Glycosylation$901,076
R01 · FY2024 · AI
Human Monoclonal Antibodies for Encephalitic Alphaviruses$798,435
R01 · FY2024 · AI
Meningeal Immunity and Viral Neuropathogenesis$769,115
R01 · FY2024 · AI · contact PI
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus$762,686
R01 · FY2024 · AI · contact PI
Pathogenesis of Alphavirus induced Chronic Arthritis and Myositis$754,069
R01 · FY2024 · AI
Project 2$699,043
U19 · FY2024 · AI · contact PI
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis$657,820
R01 · FY2024 · AI · contact PI
A new mechanism of antiviral activity of 2-5 Oligoadenylate Synthetase 1$323,830
R01 · FY2024 · AI
A new mechanism of antiviral activity of 2'-5' Oligoadenylate Synthetase 1$40,469
R01 · FY2024 · AI
Development of therapeutic pan-Alphavirus human monoclonal antibodies$2,099,526
U19 · FY2023 · AI · contact PI
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2$1,197,841
R01 · FY2023 · AI · contact PI
Human Monoclonal Antibodies for Encephalitic Alphaviruses$810,278
R01 · FY2023 · AI
Innate Immune Regulation of Zika Virus Infection$787,259
R01 · FY2023 · AI
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus$762,686
R01 · FY2023 · AI · contact PI
Structure-Function Analysis of Mxra8 Interaction with Alphaviruses.$706,887
R01 · FY2023 · AI · contact PI
Innate immune signaling in placental antiviral defenses$682,592
R01 · FY2023 · AI
Systemic Neurotropic virus infection effects on GI Dysmotility$665,032
R01 · FY2023 · DK
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis$661,548
R01 · FY2023 · AI · contact PI
Impairment of B cell Responses by Pathogenic Chikungunya Viruses$639,350
R01 · FY2023 · AI
A new mechanism of antiviral activity of 2'-5' Oligoadenylate Synthetase 1$362,789
R01 · FY2023 · AI
The Development and Evaluation of Pan-Coronavirus Vaccines$7,990,794
P01 · FY2022 · AI · contact PI
Development of Viral Vaccines against Sarbecoviruses and Merbecoviruses$2,161,141
P01 · FY2022 · AI · contact PI
Development of therapeutic pan-Alphavirus human monoclonal antibodies$1,935,706
U19 · FY2022 · AI · contact PI
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2$1,202,440
R01 · FY2022 · AI · contact PI
Antibody-based Protection against Flavivirses$950,300
R01 · FY2022 · AI · contact PI
Human Monoclonal Antibodies for Encephalitic Alphaviruses$858,139
R01 · FY2022 · AI
Innate Immune Regulation of Zika Virus Infection$796,014
R01 · FY2022 · AI
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus$762,686
R01 · FY2022 · AI · contact PI
Structure-Function Analysis of Mxra8 Interaction with Alphaviruses.$689,563
R01 · FY2022 · AI · contact PI
Systemic Neurotropic virus infection effects on GI Dysmotility$688,338
R01 · FY2022 · DK
Innate immune signaling in placental antiviral defenses$687,776
R01 · FY2022 · AI
Impairment of B cell Responses by Pathogenic Chikungunya Viruses$640,137
R01 · FY2022 · AI
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis$620,348
R01 · FY2022 · AI · contact PI
Defining the functional interface between the ER and flaviviruses$613,928
R01 · FY2022 · AI
A new mechanism of antiviral activity of 2'-5' Oligoadenylate Synthetase 1$603,822
R01 · FY2022 · AI
Administrative Core$507,955
P01 · FY2022 · AI · contact PI
Mechanisms of Zika Virus Maternal-Fetal Transmission$230,328
R01 · FY2022 · HD
Development of therapeutic pan-Alphavirus human monoclonal antibodies$1,829,048
U19 · FY2021 · AI · contact PI
Human antibody-based countermeasures against the Coronavirus SARS-CoV-2$1,206,220
R01 · FY2021 · AI · contact PI
Antibody-based Protection against Flavivirses$953,281
R01 · FY2021 · AI · contact PI
TAM Receptors and Virus Infection$833,577
R01 · FY2021 · AI
Innate Immune Regulation of Zika Virus Infection$805,011
R01 · FY2021 · AI
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus$736,692
R01 · FY2021 · AI · contact PI
Innate immune signaling in placental antiviral defenses$707,744
R01 · FY2021 · AI
Systemic Neurotropic virus infection effects on GI Dysmotility$690,112
R01 · FY2021 · DK
Human neutralizing antibodies for Zika virus$655,157
R01 · FY2021 · AI
Structure-Function Analysis of Mxra8 Interaction with Alphaviruses.$646,002
R01 · FY2021 · AI · contact PI
Impairment of B cell Responses by Pathogenic Chikungunya Viruses$641,712
R01 · FY2021 · AI
A new mechanism of antiviral activity of 2'-5' Oligoadenylate Synthetase 1$634,610
R01 · FY2021 · AI
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis$624,846
R01 · FY2021 · AI · contact PI
Defining the functional interface between the ER and flaviviruses$613,928
R01 · FY2021 · AI
Mechanisms of Zika Virus Maternal-Fetal Transmission$578,914
R01 · FY2021 · HD
Development of therapeutic pan-Alphavirus human monoclonal antibodies$1,534,561
U19 · FY2020 · AI · contact PI
Human antibody-based countermeasures against the Coronavirus SARS-CoV-2$1,193,309
R01 · FY2020 · AI · contact PI
Antibody-based Protection against Flavivirses$956,340
R01 · FY2020 · AI · contact PI
TAM Receptors and Virus Infection$833,577
R01 · FY2020 · AI
Innate Immune Regulation of Zika Virus Infection$813,373
R01 · FY2020 · AI
Chikungunya Virus Replication and Pathogenesis$716,844
R01 · FY2020 · AI
Systemic Neurotropic virus infection effects on GI Dysmotility$706,017
R01 · FY2020 · DK
Innate immune signaling in placental antiviral defenses$688,441
R01 · FY2020 · AI
Human neutralizing antibodies for Zika virus$649,057
R01 · FY2020 · AI
Impairment of B cell Responses by Pathogenic Chikungunya Viruses$634,975
R01 · FY2020 · AI
A new mechanism of antiviral activity of 2â-5â Oligoadenylate Synthetase 1$626,580
R01 · FY2020 · AI
Structure-Function Analysis of Mxra8 Interaction with Alphaviruses.$616,112
R01 · FY2020 · AI · contact PI
Defining the functional interface between the ER and flaviviruses$615,421
R01 · FY2020 · AI
Mechanisms of Zika Virus Maternal-Fetal Transmission$600,856
R01 · FY2020 · HD
IFN Dependent Control of Acute and Chronic Chikungunya Virus Induced Disease$505,745
R01 · FY2020 · AI
The DKE-121 strain as a possible new Dengue virus serotype$235,938
R21 · FY2020 · AI · contact PI
Effect of aging on neuroinvasion during West Nile virus (WNV) infection.$154,917
UH3 · FY2020 · NS
Development of therapeutic pan-Alphavirus human monoclonal antibodies$1,549,212
U19 · FY2019 · AI · contact PI
Antibody-based Protection against Flavivirses$959,574
R01 · FY2019 · AI · contact PI
Innate Immune Regulation of Zika Virus Infection$863,742
R01 · FY2019 · AI
TAM Receptors and Virus Infection$833,577
R01 · FY2019 · AI
Structural and functional basis of ultra potent CHKV neutralization by human mAbs$721,808
R01 · FY2019 · AI
Chikungunya Virus Replication and Pathogenesis$721,175
R01 · FY2019 · AI
Innate immune signaling in placental antiviral defenses$712,831
R01 · FY2019 · AI
Human neutralizing antibodies for Zika virus$644,482
R01 · FY2019 · AI
Defining the functional interface between the ER and flaviviruses$614,278
R01 · FY2019 · AI
Mechanisms of Zika Virus Maternal-Fetal Transmission$605,919
R01 · FY2019 · HD
Impairment of B cell Responses by Pathogenic Chikungunya Viruses$601,723
R01 · FY2019 · AI
IFN Dependent Control of Acute and Chronic Chikungunya Virus Induced Disease$530,526
R01 · FY2019 · AI
Structure-Function Analysis of Mxra8 Interaction with Alphaviruses.$511,257
R01 · FY2019 · AI · contact PI
The DKE-121 strain as a possible new Dengue virus serotype$195,469
R21 · FY2019 · AI · contact PI
Effect of aging on neuroinvasion during West Nile virus (WNV) infection.$154,425
UH3 · FY2019 · NS
Antibody-based Protection against Flavivirses$988,938
R01 · FY2018 · AI · contact PI
TAM Receptors and Virus Infection$833,577
R01 · FY2018 · AI
Chikungunya Virus Replication and Pathogenesis$734,664
R01 · FY2018 · AI
Structural and functional basis of ultra potent CHKV neutralization by human mAbs$725,215
R01 · FY2018 · AI
Human neutralizing antibodies for Zika virus$632,282
R01 · FY2018 · AI
Mechanisms of Zika Virus Maternal-Fetal Transmission$614,146
R01 · FY2018 · HD
Defining the functional interface between the ER and flaviviruses$566,093
R01 · FY2018 · AI
IFN Dependent Control of Acute and Chronic Chikungunya Virus Induced Disease$528,239
R01 · FY2018 · AI
CNS Innate Immune Control of Encephalitic Flaviviruses$457,500
U19 · FY2018 · AI · contact PI
Effect of aging on neuroinvasion during West Nile virus (WNV) infection.$153,072
UH3 · FY2018 · NS
Human neutralizing antibodies for Zika virus$1,327,897
R01 · FY2017 · AI
Antibody-Based Protection Against Dengue Virus$1,040,996
R01 · FY2017 · AI · contact PI
TAM Receptors and Virus Infection$857,077
R01 · FY2017 · AI
Systems Biology Identifies Restriction Factors for West Nile Virus$805,907
U19 · FY2017 · AI · contact PI
Innate Immune Control of West Nile Virus$760,880
R01 · FY2017 · AI
Chikungunya Virus Replication and Pathogenesis$740,822
R01 · FY2017 · AI
Structural and functional basis of ultra potent CHKV neutralization by human mAbs$728,541
R01 · FY2017 · AI
Mechanisms of Zika Virus Maternal-Fetal Transmission$631,786
R01 · FY2017 · HD
ISG CONTROL OF FLAVIVIRUS INFECTION$582,216
R01 · FY2017 · AI · contact PI
IFN Dependent Control of Acute and Chronic Chikungunya Virus Induced Disease$497,739
R01 · FY2017 · AI
CNS Innate Immune Control of Encephalitic Flaviviruses$440,208
U19 · FY2017 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$126,363
R01 · FY2017 · AI · contact PI
Effect of aging on neuroinvasion during West Nile virus (WNV) infection.$74,817
UH2 · FY2017 · NS
Antibody-Based Protection Against Dengue Virus$861,707
R01 · FY2016 · AI · contact PI
Systems Biology Identifies Restriction Factors for West Nile Virus$845,316
U19 · FY2016 · AI · contact PI
Innate Immune Control of West Nile Virus$760,880
R01 · FY2016 · AI
CNS Innate Immune Control of Encephalitic Flaviviruses$669,227
U19 · FY2016 · AI · contact PI
Chikungunya Virus Replication and Pathogenesis$667,588
R01 · FY2016 · AI
ISG CONTROL OF FLAVIVIRUS INFECTION$592,343
R01 · FY2016 · AI · contact PI
Structural and functional basis of ultra potent CHKV neutralization by human mAbs$496,974
R01 · FY2016 · AI
Structural and functional basis of ultra potent CHKV neutralization by human mAbs$234,811
R01 · FY2016 · AI
Chikungunya Virus Replication and Pathogenesis$97,094
R01 · FY2016 · AI
Effect of aging on neuroinvasion during West Nile virus (WNV) infection.$74,817
UH2 · FY2016 · NS
Antibody-Based Protection Against Dengue Virus$73,745
R01 · FY2016 · AI · contact PI
Structural and functional basis of ultra potent CHKV neutralization by human mAbs$761,802
R01 · FY2015 · AI
Innate Immune Control of West Nile Virus$760,880
R01 · FY2015 · AI
CNS Innate Immune Control of Encephalitic Flaviviruses$641,246
U19 · FY2015 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$640,779
R01 · FY2015 · AI · contact PI
Systems Biology Identifies Restriction Factors for West Nile Virus$619,560
U19 · FY2015 · AI · contact PI
ISG CONTROL OF FLAVIVIRUS INFECTION$603,358
R01 · FY2015 · AI · contact PI
Antibody Based Therapeuticcs for Chikungunya Virus$1,167,991
R01 · FY2014 · AI · contact PI
Innate Immune Control of West Nile Virus$737,600
R01 · FY2014 · AI
CNS Innate Immune Control of Encephalitic Flaviviruses$656,906
U19 · FY2014 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$640,779
R01 · FY2014 · AI · contact PI
ISG CONTROL OF FLAVIVIRUS INFECTION$613,232
R01 · FY2014 · AI · contact PI
Systems Biology Identifies Restriction Factors for West Nile Virus$438,493
U19 · FY2014 · AI · contact PI
Antibody Based Therapeuticcs for Chikungunya Virus$894,815
R01 · FY2013 · AI · contact PI
Innate Immune Control of West Nile Virus$713,273
R01 · FY2013 · AI
Antibody-Based Protection Against Dengue Virus$627,983
R01 · FY2013 · AI · contact PI
ISG CONTROL OF FLAVIVIRUS INFECTION$610,742
R01 · FY2013 · AI · contact PI
Systems Biology Identifies Restriction Factors for West Nile Virus$450,966
U19 · FY2013 · AI · contact PI
Complement Activation and WNV Infection$312,653
U54 · FY2013 · AI · contact PI
Antibody Based Therapeuticcs for Chikungunya Virus$944,844
R01 · FY2012 · AI · contact PI
Complement Activation and WNV Infection$313,580
U54 · FY2012 · AI · contact PI
Antibody Based Therapeuticcs for Chikungunya Virus$863,223
R01 · FY2011 · AI · contact PI
Safe Antibody Prophylaxis and Therapy Against Dengue Virus$850,625
U01 · FY2011 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$531,716
R01 · FY2011 · AI · contact PI
Complement Activation and WNV Infection$323,822
U54 · FY2011 · AI · contact PI
Safe Antibody Prophylaxis and Therapy Against Dengue Virus$853,695
U01 · FY2010 · AI · contact PI
Antibody Based Therapeuticcs for Chikungunya Virus$848,100
R01 · FY2010 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$530,087
R01 · FY2010 · AI · contact PI
Complement Activation and WNV Infection$336,167
U54 · FY2010 · AI · contact PI
Monoclonal Antibody Therapy for West Nile Virus$1,034,837
U01 · FY2009 · AI · contact PI
Safe Antibody Prophylaxis and Therapy Against Dengue Virus$837,295
U01 · FY2009 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$520,371
R01 · FY2009 · AI · contact PI
Developing small molecule therapeutics for West Nile virus$440,189
U01 · FY2009 · AI · contact PI
Complement Activation and WNV Infection$324,385
U54 · FY2009 · AI · contact PI
Monoclonal Antibody Therapy for West Nile Virus$1,025,666
U01 · FY2008 · AI · contact PI
Safe Antibody Prophylaxis and Therapy Against Dengue Virus$813,000
U01 · FY2008 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$505,214
R01 · FY2008 · AI · contact PI
B Cells, Antibody & Complement Protect Against West Nile$384,848
U54 · FY2008 · AI · contact PI
Monoclonal Antibody Therapy for West Nile Virus$1,020,909
U01 · FY2007 · AI · contact PI
Antibody-Based Protection Against Dengue Virus$500,000
R01 · FY2007 · AI · contact PI
Monoclonal Antibody Therapy for West Nile Virus$1,442,808
U01 · FY2006 · AI · contact PI
Development of Novel Antiviral Agents VS West Nile Virus$698,106
U01 · FY2006 · AI · contact PI
Development of Novel Antiviral Agents VS West Nile Virus$694,081
U01 · FY2005 · AI
Monoclonal Antibody Therapy for West Nile Virus$613,641
U01 · FY2005 · AI
Development of Novel Antiviral Agents VS West Nile Virus$683,412
U01 · FY2004 · AI
Development of Novel Antiviral Agents VS West Nile Virus$663,507
U01 · FY2003 · AI
Development of Novel Antiviral Agents VS West Nile Virus$712,013
U01 · FY2002 · AI
INTERFERON IN MODULATING DENGUE VIRUS INFECTION$117,180
K08 · FY2002 · AI
INTERFERON IN MODULATING DENGUE VIRUS INFECTION$117,180
K08 · FY2001 · AI
INTERFERON IN MODULATING DENGUE VIRUS INFECTION$65,856
K08 · FY2000 · AI
INTERFERON IN MODULATING DENGUE VIRUS INFECTION$36,617
K08 · FY2000 · AI